These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 16842381)
1. Population pharmacokinetics of tipifarnib in healthy subjects and adult cancer patients. Perez-Ruixo JJ; Piotrovskij V; Zhang S; Hayes S; De Porre P; Zannikos P Br J Clin Pharmacol; 2006 Jul; 62(1):81-96. PubMed ID: 16842381 [TBL] [Abstract][Full Text] [Related]
2. Effect of CYP2D6 genetic polymorphism on the population pharmacokinetics of tipifarnib. Perez-Ruixo JJ; Zannikos P; Ozdemir V; Franc MA; Francke S; Piotrovsky V Cancer Chemother Pharmacol; 2006 Nov; 58(5):681-91. PubMed ID: 16544144 [TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetics of APOMINE: a meta-analysis in cancer patients and healthy males. Bonate PL; Floret S; Bentzen C Br J Clin Pharmacol; 2004 Aug; 58(2):142-55. PubMed ID: 15255796 [TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of tipifarnib after oral and intravenous administration in subjects with advanced cancer. Zhang S; Zannikos P; Awada A; Piccart-Gebhart M; Dirix LY; Fumoleau P; Verhaeghe T; Francois M; De Porre P J Clin Pharmacol; 2006 Oct; 46(10):1116-27. PubMed ID: 16988200 [TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetics meta-analysis of plitidepsin (Aplidin) in cancer subjects. Nalda-Molina R; Valenzuela B; Ramon-Lopez A; Miguel-Lillo B; Soto-Matos A; Perez-Ruixo JJ Cancer Chemother Pharmacol; 2009 Jun; 64(1):97-108. PubMed ID: 18941750 [TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetic meta-analysis of trabectedin (ET-743, Yondelis) in cancer patients. Perez-Ruixo JJ; Zannikos P; Hirankarn S; Stuyckens K; Ludwig EA; Soto-Matos A; Lopez-Lazaro L; Owen JS Clin Pharmacokinet; 2007; 46(10):867-84. PubMed ID: 17854236 [TBL] [Abstract][Full Text] [Related]
7. Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis. Zhou H; Mayer PR; Wajdula J; Fatenejad S J Clin Pharmacol; 2004 Nov; 44(11):1235-43. PubMed ID: 15496641 [TBL] [Abstract][Full Text] [Related]
8. A simultaneous oral/intravenous population pharmacokinetic model for vinorelbine. Variol P; Nguyen L; Tranchand B; Puozzo C Eur J Clin Pharmacol; 2002 Oct; 58(7):467-76. PubMed ID: 12389069 [TBL] [Abstract][Full Text] [Related]
9. Population Pharmacokinetics of Total and Free Erdafitinib in Adult Healthy Volunteers and Cancer Patients: Analysis of Phase 1 and Phase 2 Studies. Dosne AG; Valade E; Stuyckens K; Li LY; Ouellet D; Perez-Ruixo JJ J Clin Pharmacol; 2020 Apr; 60(4):515-527. PubMed ID: 31742712 [TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors. Guo F; Letrent SP; Sharma A Cancer Chemother Pharmacol; 2007 Nov; 60(6):799-809. PubMed ID: 17285315 [TBL] [Abstract][Full Text] [Related]
11. Switching from body surface area-based to fixed dosing for the investigational proteasome inhibitor ixazomib: a population pharmacokinetic analysis. Gupta N; Zhao Y; Hui AM; Esseltine DL; Venkatakrishnan K Br J Clin Pharmacol; 2015 May; 79(5):789-800. PubMed ID: 25377318 [TBL] [Abstract][Full Text] [Related]
12. Bridging Olaparib Capsule and Tablet Formulations Using Population Pharmacokinetic Meta-analysis in Oncology Patients. Zhou D; Li J; Bui K; Learoyd M; Berges A; Milenkova T; Al-Huniti N; Tomkinson H; Xu H Clin Pharmacokinet; 2019 May; 58(5):615-625. PubMed ID: 30357650 [TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetics of afatinib, an irreversible ErbB family blocker, in patients with various solid tumors. Freiwald M; Schmid U; Fleury A; Wind S; Stopfer P; Staab A Cancer Chemother Pharmacol; 2014 Apr; 73(4):759-70. PubMed ID: 24522402 [TBL] [Abstract][Full Text] [Related]
14. Pooled population pharmacokinetic analysis of phase I, II and III studies of linifanib in cancer patients. Salem AH; Koenig D; Carlson D Clin Pharmacokinet; 2014 Apr; 53(4):347-59. PubMed ID: 24307488 [TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetics of HM781-36 (poziotinib), pan-human EGF receptor (HER) inhibitor, and its two metabolites in patients with advanced solid malignancies. Noh YH; Lim HS; Jung JA; Song TH; Bae KS Cancer Chemother Pharmacol; 2015 Jan; 75(1):97-109. PubMed ID: 25377158 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of single-agent axitinib across multiple solid tumor types. Tortorici MA; Cohen EE; Pithavala YK; Garrett M; Ruiz-Garcia A; Kim S; Fruehauf JP Cancer Chemother Pharmacol; 2014 Dec; 74(6):1279-89. PubMed ID: 25336084 [TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetics of PM00104 (Zalypsis(®)) in cancer patients. Pérez-Ruixo C; Valenzuela B; Fernández Teruel C; González-Sales M; Miguel-Lillo B; Soto-Matos A; Pérez-Ruixo JJ Cancer Chemother Pharmacol; 2012 Jan; 69(1):15-24. PubMed ID: 21590449 [TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetics and dosing implications for cobimetinib in patients with solid tumors. Han K; Jin JY; Marchand M; Eppler S; Choong N; Hack SP; Tikoo N; Bruno R; Dresser M; Musib L; Budha NR Cancer Chemother Pharmacol; 2015 Nov; 76(5):917-24. PubMed ID: 26365290 [TBL] [Abstract][Full Text] [Related]
19. Population Pharmacokinetic Analysis of Lanreotide Autogel/Depot in the Treatment of Neuroendocrine Tumors: Pooled Analysis of Four Clinical Trials. Buil-Bruna N; Garrido MJ; Dehez M; Manon A; Nguyen TX; Gomez-Panzani EL; Trocóniz IF Clin Pharmacokinet; 2016 Apr; 55(4):461-73. PubMed ID: 26416534 [TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetics of clofarabine and its metabolite 6-ketoclofarabine in adult and pediatric patients with cancer. Bonate PL; Cunningham CC; Gaynon P; Jeha S; Kadota R; Lam GN; Razzouk B; Rytting M; Steinherz P; Weitman S Cancer Chemother Pharmacol; 2011 Apr; 67(4):875-90. PubMed ID: 20582417 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]